PMID- 36576854
OWN - NLM
STAT- MEDLINE
DCOM- 20230216
LR  - 20230216
IS  - 1473-2165 (Electronic)
IS  - 1473-2130 (Linking)
VI  - 22
IP  - 2
DP  - 2023 Feb
TI  - Selective photothermolysis with a novel 1726 nm laser beam: A safe and effective 
      solution for acne vulgaris.
PG  - 486-496
LID - 10.1111/jocd.15602 [doi]
AB  - BACKGROUND: Selective photothermolysis on sebaceous glands is an effective method 
      for treating acne vulgaris (AV); however, safety, efficacy, and discomfort hinder 
      its utilization in clinical settings. AIMS: The primary objective is to evaluate 
      the safety and efficacy of a novel 1726 nm laser with contact cooling to treat 
      AV. METHODS: Seventeen patients aged 18 to 36 were enrolled and treated in this 
      IRB-approved, single-center, open-label study. Patients received up to three 
      facial laser sessions up to seven weeks apart. Follow-up visits happened ten days 
      post-session and at the 4 and 12 weeks following the final session. The 
      investigator assessed the severity of device-related adverse events (AEs). 
      Investigator Global Assessment (IGA) and inflammatory lesion counts (ILC) were 
      used as metrics to evaluate acne resolution and skin condition enhancement. 
      Patients' perspectives on satisfaction and comfort using this technology were 
      assessed using Subject Experience Questionnaires (SEQ). RESULTS: Safety 
      assessment showed mild and transient AEs. All subjects tolerated anesthetics-free 
      treatments well, with a mean treatment discomfort score of 4.9 +/- 1.5. Compared to 
      baseline, a statistically significant reduction in ILC (p = 0.003) of 52% to 56% 
      is achieved four to twelve weeks following treatment. Long-term follow-ups showed 
      progressive improvement 24 months post-treatment with a 97% reduction in ILC. 
      SEQs revealed high subject satisfaction (71%) with psychosocial improvement three 
      months post-treatment. CONCLUSION: The novel 1726 nm laser appears safe and 
      effective for treating mild-to-severe acne. Acne resolution is apparent within 
      the first month and progresses beyond the study duration.
CI  - (c) 2022 Cutera Inc. Journal of Cosmetic Dermatology published by Wiley Periodicals 
      LLC.
FAU - Goldberg, David
AU  - Goldberg D
AUID- ORCID: 0000-0002-1465-0691
AD  - Dermatology, Icahn School of Medicine at Mt. Sinai, New York, New York City, USA.
FAU - Kothare, Amogh
AU  - Kothare A
AD  - Cutera, Inc., California, Brisbane, USA.
FAU - Doucette, Margot
AU  - Doucette M
AD  - Cutera, Inc., California, Brisbane, USA.
FAU - Kaur, Arshdeep
AU  - Kaur A
AD  - Cutera, Inc., California, Brisbane, USA.
FAU - Ronan, Stephen
AU  - Ronan S
AD  - Blackhawk Plastic Surgery and MedSpa, California, Danville, USA.
FAU - Fromowitz, Jeffrey
AU  - Fromowitz J
AD  - Dermatology, Schmidt College of Medicine, Florida Atlantic University, Florida, 
      Boca Raton, USA.
FAU - Hamidi-Sakr, Amer
AU  - Hamidi-Sakr A
AUID- ORCID: 0000-0001-9398-8502
AD  - Cutera, Inc., California, Brisbane, USA.
LA  - eng
GR  - Cutera Inc./
PT  - Clinical Trial
PT  - Journal Article
DEP - 20221228
PL  - England
TA  - J Cosmet Dermatol
JT  - Journal of cosmetic dermatology
JID - 101130964
SB  - IM
MH  - Humans
MH  - *Acne Vulgaris/radiotherapy/pathology
MH  - Lasers
MH  - Light
MH  - Sebaceous Glands
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Diode laser
OT  - Photothermolysis
OT  - Sebaceous glands
OT  - acne vulgaris
OT  - dermatology
EDAT- 2022/12/29 06:00
MHDA- 2023/02/14 06:00
CRDT- 2022/12/28 12:42
PHST- 2022/11/28 00:00 [revised]
PHST- 2022/10/18 00:00 [received]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2022/12/29 06:00 [pubmed]
PHST- 2023/02/14 06:00 [medline]
PHST- 2022/12/28 12:42 [entrez]
AID - 10.1111/jocd.15602 [doi]
PST - ppublish
SO  - J Cosmet Dermatol. 2023 Feb;22(2):486-496. doi: 10.1111/jocd.15602. Epub 2022 Dec 
      28.